STAT3 and ovarian carcinoma: Because PARPi combination with VEGF-inhibiting antibody bevacizumab has been shown to significantly improve progression-free survival in an ongoing recurrent ovarian cancer clinical trial (55), STAT3 inhibition may also improve PARPi effects through VEGF downregulation.